XUHC:XETRA:XETRA-Xtrackers MSCI USA Health Care UCITS ETF 1D EUR (EUR)

ETF | Others |

Last Closing

USD 53.48

Change

-1.84 (-3.33)%

Market Cap

N/A

Volume

2.36K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-11 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

-1.17 (-2.58%)

USD 96.80B
EUNL:XETRA iShares Core MSCI World UCITS ..

-1.93 (-1.96%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-0.49 (-2.11%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

-0.22 (-1.65%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

-0.13 (-2.51%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

-0.29 (-1.27%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

-0.27 (-2.08%)

USD 23.43B
PPFB:XETRA iShares Physical Gold ETC EUR

-0.16 (-0.31%)

USD 19.49B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

-0.21 (-2.04%)

USD 12.83B
EUN5:XETRA iShares Core Corporate Bond UC..

-0.54 (-0.45%)

USD 12.26B

ETFs Containing XUHC:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.43% 62% D 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.43% 62% D 57% F
Trailing 12 Months  
Capital Gain -0.85% 22% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.85% 23% F 27% F
Trailing 5 Years  
Capital Gain 72.32% 53% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.32% 53% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 11.11% 67% D+ 66% D+
Dividend Return 11.19% 66% D+ 65% D
Total Return 0.08% 10% F 6% D-
Risk Return Profile  
Volatility (Standard Deviation) 10.63% 60% D- 68% D+
Risk Adjusted Return 105.26% 89% A- 91% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.